Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles

Journal of Pharmaceutical Sciences

Volumn 103, Issue 1, 2014, Pages 78-89

  Shomali, Maliheh ^a   Freitag, Angelika ^b   Engert, Julia ^b   Siedler, Michael ^c   Kaymakcalan, Zehra ^c   Winter, Gerhard ^b   Carpenter, John F ^d   Randolph, Theodore W ^a  

^a UCB 450   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

adjuvant effect; adsorption; aggregates; anti drug antibody (ADA); ELISA assay; immunogenicity; infrared spectroscopy; microparticles; monoclonal antibody (mAb); protein

Indexed keywords

GLASS; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY;

ADSORPTION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; MOUSE; MOUSE STRAIN; NONHUMAN;

ADJUVANT EFFECT; ADSORPTION; AGGREGATES; ANTI-DRUG ANTIBODY (ADA); ELISA ASSAY; IMMUNOGENICITY; INFRARED SPECTROSCOPY; MICROPARTICLES; MONOCLONAL ANTIBODY (MAB); PROTEIN;

ADSORPTION; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 84890560538     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23772     Document Type: Article

References (63)

1. Rosenberg AS,. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8: E501-E507.
2. Randolph TW, Carpenter JF,. 2007. Engineering challenge of protein formulations. AICHE J 53: 1902-1907.
3. Aarden L, Ruuls SR, Wolbink G,. 2008. Immunogenicity of anti-tumor necrosis factor antibodies-Toward improved methods of anti-antibody measurement. Curr Opin Immunol 20: 431-435.
4. Anderson PJ,. 2005. Tumor necrosis factor inhibitors: Clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 34: 19-22.
5. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD,. 2010. Have we overestimated the benefit of human(ized) antibodies?. MAbs 2: 682-694.
6. Ring J, Seifert J, Jesch F, Brendel W,. 1977. Anaphylactoid reactions due to non-immune complex serum protein aggregates. Monogr Allergy 12: 27-35.
7. Pedotti R, Mitchell D, Wedemeyer J, Karpuj M, Chabas D, Hattab EM, Tsai M, Galli SJ, Steinman L,. 2001. An unexpected version of horror autotoxicus: Anaphylactic shock to a self-peptide. Nat Immunol 2: 216-222.
8. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PCF, Van der Woude CJ,. 2008. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 28: 1122-1126.
9. Baert F, Noman M, Vermiere S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P,. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348: 601-608.
10. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A,. 2011. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheum 50: 1445-1452.
11. Plasencia C., 2012. Influence of immunogenicity on the efficacy of long-term treatment spondyloarthritis with infliximab. Ann Rheum Dis 71: 1955-1960.
12. Braun A, Kwee L, Labow MA, Alsenz J,. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha in normal and transgenic mice. Pharm Res 14: 1472-1478.
13. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W,. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22: 1997-2006.
14. Fradkin AH, Carpenter JF, Randolph TW,. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98: 3247-3264.
15. Van Beers MMC, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W,. 2010. Aggregated recombinant human interferon beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm Res 27: 1812-1824.
16. Weksler ME, Bull G, Schwawrz GH, Stenzel KH, Rubin AL,. 1970. Immunologic responses of graft recipients. J Clin Invest 49: 1589-1595.
17. Dresser D,. 1962. Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunol 5: 378-388.
18. Biro CE, Garcia G,. 1965. The antigenicity of aggregated and aggregate-free human gamma-globulin for rabbits. Immunol 8: 411-419.
19. Gamble C,. 1966. The role of aggregates in the primary immune response of mice to human gamma globulin. Int Arch Allergy Appl Immunol 30: 446-455.
20. Sassen A, Perkins EH, Brown RA,. 1968. Immunogenic potency of human gamma-globulin in mice. Immunology 14: 247-256.
21. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich CH Jr, Carpenter JF,. 2009. IgG particle formation during filling pump operation: A case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98: 94-104.
22. Freitag A, Shomali M,. 2013. Detection of anti-drug antibodies in murine serum samples: The need for immune complex dissociation. Unpublished Results.
23. Wen Z, Torraca G, Masatani P, Sloey C, Phillips J,. 2012. Nondestructive detection of glass vial inner surface. J Pharm Sci 101: 1378-1384.
24. US FDA. 2011. Advisory to drug manufacturers: Formation of glass lamellae in certain injectable drug. Accessed, at: http://www.fda.gov/drugs/drugsafety/ ucm248490.htm on 11/03/2013.
25. Fradkin AH, Carpenter JF, Randolph TW,. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100: 4953-4964.
26. Van Beers MMC, Gilli F, Schellekens H, Randolph TW, Jiskoot WIM,. 2012. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 101: 187-199.
27. Fujiwara M,. 1977. Cellular mechanisms of the resistance to the induction of immunological tolerance. Immunol 32: 783-791.
28. Das S, Leskowitz S,. 1974. The cellular basis for tolerance or immunity to bovine-gamma-globulin in mice. J Immunol 112: 107-114.
29. Golub ES, Weigle WO,. 1969. Studies on the induction of immunologic unresponsiveness: III. Antigen form and mouse strain variation. J Immunol 102: 389-396.
30. Martin RM, Brady JL, Lew AM,. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J Immunol Methods 212: 187-192.
31. Seppälä I, Sarvas H, Péterfy F, Mäkelä O,. 1981. The four subclasses of IgG can be isolated from mouse serum by using protein A-sepharose. Scand J Immunol 14: 335-342.
32. Bee JS, Chiu D, Sawicki S, Stevenson JL, Chatterjee K, Freund E, Carpenter JF, Randolph TW,. 2009. Monoclonal antibody interactions with micro- and nanoparticles: Adsorption, aggregation, and accelerated stress studies. J Pharm Sci 98: 3218-3238.
33. Haynes CA, Norde W,. 1994. Globular proteins at solid/liquid interfaces. Colloids Surfaces B: Biointerfaces 2: 517-566.
34. Dong A, Huang P, Caughey WS,. 1990. Protein secondary structures in water from second-derivative amide I infrared spectra. Biochem 29: 3303-3308.
35. Buijs J, Norde W, Lichtenbelt JWT,. 1996. Changes in the secondary structure of adsorbed IgG and F(ab') 2 studied by FTIR spectroscopy. Langmuir 12: 1605-1613.
36. Giacomelli C, Bremer M, Norde W,. 1999. ATR-FTIR study of IgG adsorbed on different silica surfaces. J Colloid Interface Sci 220: 13-23.
37. Eftink MR, Ghiron CA,. 1981. Fluorescence quenching studies with proteins. Biochem 114: 199-227.
38. Eftink M, Ghiron C,. 1977. Exposure of tryptophanyl residues and protein dynamics. Biochem 16: 5546-5551.
39. Lakowicz JR,. 1999. Principles of fluorescence spectroscopy. 2nd ed. New York: Springer.
40. Malyala P, Singh M,. 2008. Endotoxin limits in formulations for preclinical research. J Pharm Sci 97: 2041-2044.
41. Maas C, Hermeling S, Bouma B, Jiskoot W, Gebbink MF,. 2007. A role for protein misfolding in immunogenicity of biopharmaceuticals. J Biol Chem 282: 2229-2236.
42. Hermeling S, Jiskoot W, Crommelin D, Bornaes C, Schellekens H,. 2005. Development of a transgenic mouse model immune tolerant for human interferon Beta. Pharm Res 22: 847-851.
43. Wilson-welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B,. 2009. Vaccine adjuvants: Current challenges and future approaches. J Pharm Sci 98: 1278-1316.
44. HogenEsch H,. 2002. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20: S34-S39.
45. Patton A, Mullenix MC, Swanson SJ, Koren E,. 2005. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 304: 189-195.
46. Hoehne M, Samuel F, Dong A, Wurth C, Mahler H, Carpenter JF, Randolph TW,. 2011. Adsorption of monoclonal antibodies to glass microparticles. J Pharm Sci 100: 123-132.
47. Murphy K, Travers P, Walport M,. 2008. Janeway's immunobiology. 7th ed, Garland Science, New York and London.
48. Dresser D,. 1961. Acquired immunological tolerance to a fraction of bovine gamma globulin. Immunology 4: 13-23.
49. Dresser D, Gowland G,. 1964. Immunological paralysis induced in adult rabbits by small amount of a protein antigen. Nature 203: 733-736.
50. Petrovsky N, Aguilar JC,. 2004. Vaccine adjuvants: Current state and future trends. Immunol Cell Bio 82: 488-496.
51. McKee AS, Munks MW, MacLeod MKL, Fleenor CJ, Van Rooijen N, Kappler JW, Marrack P,. 2009. Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity. J Immunol 183: 4403-4414.
52. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA,. 2008. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453: 1122-1126.
53. Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, Van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J,. 2008. Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J immunol 181: 3755-3759.
54. Dresser DW,. 1968. An assay for adjuvanticity. Clin Exp immunol 3: 877-888.
55. Rosenberg YJ,. 1981. The ability of nonspecific T-cell stimulators to induce helper-cell-dependent increases in either polyclonal or isotype-restricted l g production in vivo. Cell Immunol 61: 416-424.
56. Mond JJ, Vos Q, Lees A, Snapper CM,. 1995. T cell independent antigens. Curr Opin Immunol 7: 349-354.
57. Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM,. 2010. Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med 207: 1485-1500.
58. Perlmutter RM, Hansburg D, Briles DE, Robert A, David JM,. 1978. Subclass restriction of murine anti-carbohydrate antibodies. J Immunol 121: 566-572.
59. Snapper CM, McIntyre TM, Mandler R PL,. 1992. Induction of IgG3 secretion by interferon gamma: A model for T-cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med 175: 1367-1371.
60. Filipe V,. July 19-21, 2011. IgG monoclonal antibody aggregates: In vitro characterization in human serum and in vivo imaging in a mouse model. Poster presented at the Colorado Protein Stability Conference, Breckenridge, Colorado.
61. Tangye SG, Tarlinton DM,. 2009. Memory B cells: Effectors of long-lived immune responses. Eur J Immunol 39: 2065-2075.
62. Dintzis HM, Vogelstein B,. 1976. Molecular determinants of immunogenicity: The immune model of immune response. Proc Natl Acad Sci USA 73: 3671-3675.
63. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V,. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287: 25266-25279.